[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-lymphocytic-leukemia:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Lymphocytic Leukemia","MS4A1 Gene",5,[8,16,23,30,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[12],"Phase 3","RECRUITING","2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07218510","Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial",[20],"Phase 2","2026-08-26T02:16:15.345907Z","2026-05-05T02:35:31.644407Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06542250","A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R\u002FR B-Cell Malignancies.",[27],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:29.470752Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[40],"Phase 1","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z"]